肿瘤细胞治疗研究
英文原题：CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting.
由于对自相残杀的担忧，用于治疗 T 细胞恶性肿瘤的 CAR T 细胞的临床开发落后于 B 细胞恶性肿瘤。
出于对自相残杀的担忧，CAR T 细胞治疗 T 细胞恶性肿瘤的临床开发落后于治疗 B 细胞恶性肿瘤。研究者正尝试调整 T 细胞生物标志物，使重新工程化的 CAR T 细胞可靶向 T 细胞恶性肿瘤。CD3 和 CD7 是两种泛 T 细胞表面标志物；研究者通过基因组碱基编辑技术或蛋白表达阻断方式敲除或敲低这些标志物，使重新工程化 T 细胞能够靶向其他 T 细胞而不发生自相残杀。本文总结 2022 年 ASH 年会上有关 CAR T 细胞治疗 T 细胞白血病/淋巴瘤的多篇最新报告，并更新 TvT CAR7、RD-13-01 和 CD7 CART 临床试验进展。
Due to the concern of fratricide, clinical development of CAR T cells for the therapy of T cell malignancies lags behind that for B cell malignancies. Attempts are being made to revise T cell biomarkers so that the re-engineered CAR T cells can target T cell malignancies. CD3 and CD7 are the two pan-T cell surface biomarkers that have been either knocked out or knocked down through genome base- editing technology or by protein expression blockers so that the re-engineered T cells can target T cells without fratricide. We summarized several latest reports on the CAR T cells for the therapy of T cell leukemia /lymphoma from the 2022 ASH Annual Meeting, with latest updates on clinical trials of TvT CAR7, RD-13-01, and CD7 CART.
MEMBER ACCOUNT
登录成功会直接打开下一页。
